Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression.
Gut microbiota
Invasive manner
Non-alcoholic fatty liver disease
Short-chain fatty acids
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
24
02
2024
accepted:
11
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
27
9
2024
Statut:
epublish
Résumé
Dysregulation of the gut microbiome has associated with the occurrence and progression of non-alcoholic fatty liver disease (NAFLD). To determine the diagnostic capacity of this association, we compared fecal microbiomes across 104 participants including non-NAFLD controls and NAFLD subtypes patients that were distinguished by magnetic resonance imaging. We measured their blood biochemical parameters, 16 S rRNA-based gut microbiota and fecal short-chain fatty acids (SCFAs). Multi-omic analyses revealed that NAFLD patients exhibited specific changes in gut microbiota and fecal SCFAs as compared to non-NAFLD subjects. Four bacterial genera (Faecalibacterium, Subdoligranulum, Haemophilus, and Roseburia) and two fecal SCFAs profiles (acetic acid, and butyric acid) were closely related to NAFLD phenotypes and could accurately distinguish NAFLD patients from healthy non-NAFLD subjects. Twelve genera belonging to Faecalibacterium, Subdoligranulum, Haemophilus, Intestinibacter, Agathobacter, Lachnospiraceae_UCG-004, Roseburia, Butyricicoccus, Actinomycetales_unclassified, [Eubacterium]_ventriosum_group, Rothia, and Rhodococcus were effective to distinguish NAFLD subtypes. Of them, combination of five genera can distinguish effectively mild NAFLD from non-NAFLD with an area under curve (AUC) of 0.84. Seven genera distinguish moderate NAFLD with an AUC of 0.83. Eight genera distinguish severe NAFLD with an AUC of 0.90. In our study, butyric acid distinguished mild-NAFLD from non-NAFLD with AUC value of 0.83. And acetic acid distinguished moderate-NAFLD and severe-NAFLD from non-NAFLD with AUC value of 0.84 and 0.70. In summary, our study and further analysis showed that gut microbiota and fecal SCFAs maybe a method with convenient detection advantages and invasive manner that are not only a good prediction model for early warning of NAFLD occurrence, but also have a strong ability to distinguish NAFLD subtypes.
Identifiants
pubmed: 39333290
doi: 10.1038/s41598-024-72909-8
pii: 10.1038/s41598-024-72909-8
doi:
Substances chimiques
Fatty Acids, Volatile
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22385Subventions
Organisme : Huai'an City Science and Technology Project under Grant
ID : HABL202261
Organisme : the Fundamental Research Funds for the Central Universities under Grant
ID : JUSRP123080
Organisme : Jiangsu Maternal and Child Health Research Project (2022)
ID : F202212
Organisme : National Natural Science Foundation of China under Grant
ID : 82073551
Informations de copyright
© 2024. The Author(s).
Références
Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med.390(6), 497–509 (2024).
doi: 10.1056/NEJMoa2309000
pubmed: 38324483
Chalasani, N. P. et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp. Clin. Trials. 30(1), 88–96 (2009).
doi: 10.1016/j.cct.2008.09.003
pubmed: 18804555
Lin, D. F. et al. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice. Free Radic. Biol. Med.195, 199–218 (2023).
doi: 10.1016/j.freeradbiomed.2022.12.087
pubmed: 36586452
Hoyles, L. et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat. Med.24(7), 1070 (2018).
doi: 10.1038/s41591-018-0061-3
pubmed: 29942096
pmcid: 6140997
Aron-Wisnewsky, J. et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol.17(5), 279–297 (2020).
doi: 10.1038/s41575-020-0269-9
pubmed: 32152478
Jennison, E. C. D. & Byrne. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin. Mol. Hepatol.27(1), 22–43 (2021).
doi: 10.3350/cmh.2020.0129
pubmed: 33291863
Koning, M. et al. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies. Gut Microbes, 15(1). (2023).
Iwaki, M. et al. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol.36(8), 2275–2284 (2021).
doi: 10.1111/jgh.15487
pubmed: 33709477
Leung, H. et al. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci. Transl. Med.14(648), eabk0855 (2022).
doi: 10.1126/scitranslmed.abk0855
pubmed: 35675435
pmcid: 9746350
Li, F. et al. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis. Lipids Health Dis.20(1), 22 (2021).
doi: 10.1186/s12944-021-01440-w
pubmed: 33637088
pmcid: 7908766
Imajo, K. et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 150(3), 626–637.e7 (2016).
doi: 10.1053/j.gastro.2015.11.048
pubmed: 26677985
Bedossa, P. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: why liver biopsy is essential. Liver Int.38, 64–66 (2018).
doi: 10.1111/liv.13653
pubmed: 29427497
Sharpton, S. R. et al. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell. Metab.33(1), 21–32 (2021).
doi: 10.1016/j.cmet.2020.11.010
pubmed: 33296678
Vallianou, N. et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules, 12(1). (2021).
Duarte, S. M. B. et al. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann. Hepatol.18(3), 416–421 (2019).
doi: 10.1016/j.aohep.2019.04.006
pubmed: 31036494
Ren, S. M. et al. Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,27(5), 369–375. (2019).
Sharma, S. P. et al. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J. Gastroenterol.27(37), 6161–6179 (2021).
doi: 10.3748/wjg.v27.i37.6161
pubmed: 34712025
pmcid: 8515797
Del Barrio, M. et al. Faecal microbiota transplantation, paving the way to treat non-alcoholic fatty liver disease. Int. J. Mol. Sci., 24(7). (2023).
Miquel, S. et al. Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii. Gut Microbes. 5(2), 146–151 (2014).
doi: 10.4161/gmic.27651
pubmed: 24637606
pmcid: 4063839
Chen, Z. et al. Association of insulin resistance and type 2 diabetes with gut microbial diversity: a microbiome-wide analysis from population studies. JAMA Netw. Open.4(7), e2118811 (2021).
doi: 10.1001/jamanetworkopen.2021.18811
pubmed: 34323983
pmcid: 8322996
Che, L. et al. Inter-correlated gut microbiota and SCFAs changes upon antibiotics exposure links with rapid body-mass gain in weaned piglet model. J. Nutr. Biochem.74, 108246 (2019).
doi: 10.1016/j.jnutbio.2019.108246
pubmed: 31671360
Hu, Y. H. et al. Gut microbiome and stages of diabetes in middle-aged adults: CARDIA microbiome study. Nutr. Metab. 20(1) (2023).
Xiao, Y. et al. Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling. Exp. Mol. Med.50(12), 1–14 (2018).
doi: 10.1038/s12276-018-0181-3
pubmed: 30504803
pmcid: 6269533
Koh, A. et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 165(6), 1332–1345 (2016).
doi: 10.1016/j.cell.2016.05.041
pubmed: 27259147
Torp Austvoll, C. et al. Health impact of the Anthropocene: the complex relationship between gut microbiota, epigenetics, and human health, using obesity as an example. Glob Health Epidemiol. Genom. 5, e2 (2020).
doi: 10.1017/gheg.2020.2
pubmed: 32363032
pmcid: 7176587
Kim, M. et al. Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing’s syndrome. Korean J. Physiol. Pharmacol.22(1), 23–33 (2018).
doi: 10.4196/kjpp.2018.22.1.23
pubmed: 29302209
Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464(7285), 59–65 (2010).
doi: 10.1038/nature08821
pubmed: 20203603
pmcid: 3779803
Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 352(6285), 565–569 (2016).
Song, H. et al. Evaluation of prebiotics through an in vitro gastrointestinal digestion and fecal fermentation experiment: further idea on the implementation of machine learning technique. Foods, 11(16). (2022).
Zhang, X. et al. Imbalance of microbacterial diversity is associated with functional prognosis of stroke. Neural Plasticity, 2023. (2023).
Effenberger, M. et al. A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma. Hepatol. Commun.7(7), (2023).
Ikeda, T. A. et al. Short-chain Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases. Pharmacol. Ther.. 239 (2022).
Hou, D. Z. et al. Alteration of fecal microbiome and metabolome by mung bean coat improves diet-induced non-alcoholic fatty liver disease in mice. Food Sci. Hum. Wellness. 11(5), 1259–1272 (2022).
doi: 10.1016/j.fshw.2022.04.023
Kondo, T. et al. Acetic acid upregulates the expression of genes for fatty acid oxidation enzymes in liver to suppress body fat accumulation. J. Agric. Food Chem.57(13), 5982–5986 (2009).
doi: 10.1021/jf900470c
pubmed: 19469536
Morrison, D. J. T. & Preston formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 7(3), 189–200 (2016).
doi: 10.1080/19490976.2015.1134082
pubmed: 26963409
pmcid: 4939913
Sarkar, A. et al., Butyrate limits inflammatory macrophage niche in NASH. Cell Death Dis.14(5) (2023).
Liu, W. et al. A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier. Eur. J. Nutr.60(5), 2317–2330 (2021).
doi: 10.1007/s00394-020-02431-w
pubmed: 33180143
Roychowdhury, S. et al. A designer synbiotic attenuates chronic-binge ethanol-induced gut-liver injury in mice. Nutrients, 11(1). (2019).
Ye, J. et al. Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function, attenuating inflammation and reducing endotoxin levels. Front. Microbiol.9, 1967 (2018).
Scheiman, J. et al. Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism. Nat. Med.25(7), 1104–1109 (2019).
doi: 10.1038/s41591-019-0485-4
pubmed: 31235964
pmcid: 7368972
Zhang, J. et al. Effect of okra fruit powder supplementation on metabolic syndrome and gut microbiota diversity in high fat diet-induced obese mice. Food Res. Int.130, 108929 (2020).
doi: 10.1016/j.foodres.2019.108929
pubmed: 32156377
Tengeler, A. C. et al. Propionic acid and not caproic acid, attenuates nonalcoholic steatohepatitis and improves (cerebro) vascular functions in obese Ldlr-/-.Leiden mice. FASEB J.34(7), 9575–9593 (2020).
doi: 10.1096/fj.202000455R
pubmed: 32472598
Louis, P. H. J. & Flint. Formation of propionate and butyrate by the human colonic microbiota. Environ. Microbiol.19(1), 29–41 (2017).
doi: 10.1111/1462-2920.13589
pubmed: 27928878
Da Silva, H. E. et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci. Rep.8(1), 1466 (2018).
doi: 10.1038/s41598-018-19753-9
pubmed: 29362454
pmcid: 5780381
De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. USA107(33), 14691–14696 (2010).
doi: 10.1073/pnas.1005963107
pubmed: 20679230
pmcid: 2930426
Bellentani, S. et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med.132(2), 112–117 (2000).
doi: 10.7326/0003-4819-132-2-200001180-00004
pubmed: 10644271
Williams, C. D. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 140(1), 124–131 (2011).
doi: 10.1053/j.gastro.2010.09.038
pubmed: 20858492
Li, Z. et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J. Gastroenterol. Hepatol.29(1), 42–51 (2014).
doi: 10.1111/jgh.12428
pubmed: 24219010
Castera, L. et al. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology156(5) (2019).
Nogami, A. et al. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD. Sci. Rep.12(1), 21925 (2022).
doi: 10.1038/s41598-022-25843-6
pubmed: 36535977
pmcid: 9763419
Garteiser, P., Castera L., et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. JHEP Rep. Innov. Hepatol.3(6), 100381 (2021).